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CObjective: In the absence of head-to-head randomized trials, indirect
comparisons of treatments across separate trials can be performed.
However, these analyses may be biased by cross-trial differences in
patient populations, sensitivity to modeling assumptions, and differ-
ences in the definitions of outcome measures. The objective of this
study was to demonstrate how incorporating individual patient data
(IPD) from trials of one treatment into indirect comparisons can ad-
dress several limitations that arise in analyses based only on aggregate
data. Methods: Matching-adjusted indirect comparisons (MAICs) use
IPD from trials of one treatment to match baseline summary statistics
reported from trials of another treatment. After matching, by using an
approach similar to propensity score weighting, treatment outcomes
are compared across balanced trial populations. This method is illus-
trated by reviewing published MAICs in different therapeutic areas. A
novel analysis in attention deficit/hyperactivity disorder further dem-
onstrates the applicability of the method. The strengths and limita-
tions of MAICs are discussed in comparison to those of indirect com-
parisons that use only published aggregate data. Results: Example O
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http://dx.doi.org/10.1016/j.jval.2012.05.004applications were selected to illustrate how indirect comparisons
based only on aggregate data can be limited by cross-trial differ-
ences in patient populations, differences in the definitions of out-
come measures, and sensitivity to modeling assumptions. The use
of IPD andMAIC is shown to address these limitations in the selected
examples by reducing or removing the observed cross-trial differ-
ences. An important assumption of MAIC, as in any comparison of
nonrandomized treatment groups, is that there are no unobserved
cross-trial differences that could confound the comparison of
outcomes. Conclusions: Indirect treatment comparisons can be lim-
ted by cross-trial differences. By combining IPD with published aggre-
ate data, MAIC can reduce observed cross-trial differences and pro-
ide decision makers with timely comparative evidence.
eywords: comparative effectiveness, individual patient data, match-
ng-adjusted indirect comparison.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health care decision makers face significant gaps between their
needs for comparative effectiveness research (CER) and the limited
availability of comparative data. The gap is particularly pronounced
for new treatments, which are often integrated into treatment strat-
egies and formulary policies without the benefits of randomized tri-
als against all clinically or economically relevant alternatives. After
the new treatment becomes available, observational studies based
on registries or real-world data, or pragmatic trials, may be initiated.
Such studies, however, will not provide reliable comparative evi-
dence until sufficient outcomes data have accumulated. This delay
in comparative evidence for new treatments reduces the value of
CER for improving the decisions of physicians, payers, and patients.
An increasingly used approach for timely CER is the compari-
son of treatment outcomes across separate randomized trials. De-
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Published by Elsevier Inc.tailed reviews of methodologies for such indirect comparisons
have been published [1,2], and guidelines have been developed for
researchers and decision makers [3–10]. By combining trials with
overlapping comparator groups, multiple direct and indirect com-
parisons can be combined into a networkmeta-analysis that sum-
marizes comparative evidence for all treatments in a therapeutic
area. Although based on randomized trials, indirect comparisons
and network meta-analyses involve comparisons of nonrandom-
ized treatment groups and are akin to observational studies and
subject to important limitations.
In particular, cross-trial differences in patients’ baseline
characteristics or differences in outcome definitions can bias
indirect comparisons [1,2,11]. Although meta-regressions can
adjust for cross-trial differences in baseline characteristics at
an aggregate level, they cannot adjust for large numbers of
baseline differences and may be subject to ecological bias
[12,13]. A key assumption of indirect comparisons and network
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941V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 0 – 9 4 7meta-analyses is that cross-trial differences can bemitigated by
measuring treatment effects relative to a common comparator
(e.g., placebo). However, different modeling assumptions, em-
bodied in the choice of a relative effect measure (e.g., relative
risk, odds ratio, or risk difference), can lead to conflicting con-
clusions about comparative effectiveness. These limitations are
difficult to address by using only published aggregate data, es-
pecially when only small numbers of trials are available.
In this article, we show that the use of individual patient data
(IPD) from clinical trials for one treatment—but not necessarily all
treatments—can address these limitations and that useful IPD are
more readily available than currently appreciated. If IPD were
available from all trials of interest, potential biases stemming from
cross-trial differences could be mitigated by regression adjustment
[14–18] or propensity scores [19,20]. Although IPD are seldom avail-
ble for all trials, researchers engaged in CER can often access IPD for
ome trials. In particular, when CER is conducted or funded by a
linical trial sponsor, IPD could be available from the sponsor’s trials.
recently developed statistical method—matching-adjusted indirect
comparison (MAIC)—can combine IPD for some treatments with pub-
lished summary data for comparator treatments. Through exam-
ples, we show how the incorporation of IPD into indirect compari-
sons via MAIC can 1) adjust for cross-trial differences in baseline
characteristics, 2) reduce sensitivity to effect measures, 3) resolve
differences in study outcome definitions, and 4) allow the compari-
son of clinically relevant dosages.
Methods
The MAIC approach has been published previously and is briefly
reviewed below [21]. The approach can be applied in three steps.
Clinical trial selection
As in any data synthesis, a systematic review should be con-
ducted to identify clinical trials for the treatments to be com-
pared. Characteristics of the selected trials should then be care-
fully compared, including the study design (e.g., randomized or
open-label trial), inclusion/exclusion criteria, baseline charac-
teristics, outcome assessments (e.g., definitions of outcomes,
schedule of assessments), and statistical methods (e.g., han-
dling of early dropouts, baseline adjustment). Cross-trial differences
in these features can be sources of heterogeneity in any meta-anal-
ysis. In indirect comparisons and network meta-analyses, these dif-
ferences canalsobe sourcesof bias. Theavailabilityof IPD,whichcan
provide opportunities to remove or reduce observed cross-trial dif-
ferences, should be assessed for each trial.
Identification of outcome measures
Ameaningful cross-trial comparison should focus on comparably
defined outcomemeasures that are available in the included trials.
The precise definition of the study outcomes, the schedule of as-
sessments, the clinical relevance of different dosages, and the sta-
tistical methods used to summarize effects should all be consid-
ered. IPD should be reanalyzed to match the outcome definitions
used in the published trial data asmuch as possible beforemaking
an indirect comparison. If outcome definitions cannot bematched
exactly, sensitivity analyses should be considered.
Matching trial populations
In trials with IPD, patients who could not have enrolled in the
published comparator trials (e.g., because of stricter inclusion/
exclusion criteria) should be excluded from the indirect com-
parison analysis. Even after matching inclusion/exclusion cri-
teria across trials, important cross-trial differences in patients’
baseline characteristics can remain. To adjust for these differ-ences by using MAIC, patients in trials with IPD are weighted
such that their weighted mean baseline characteristics match
those reported for the trials without IPD. This approach is a
form of propensity score weighting in which patients in one
treatment group (in this case the trial with IPD) are weighted by
their inverse odds of being in that group versus the other treat-
ment group (in this case the trial with only published aggregate
data). The propensity scoremodel can be estimated by using the
generalized method of moments based on the aggregate data
and IPD. Other baseline summary statistics such as medians
and standard deviations can also be matched when available.
Outcomes from common comparator arms (e.g., placebo) can be
used to validate the matching process. After matching, contin-
uous, binary, or time-to-event outcomes can be compared
across balanced trial populations by using weighted statistical
tests that incorporate the same weights developed in the
matching process (e.g., using weighted t tests, weighted 2 tests,
or Kaplan-Meier tests). Weighted statistical models (e.g., anal-
ysis of covariance) can also be used to ensure that similar meth-
ods are applied to all trials. Limitations of the MAIC approach
are described in the Discussion section.
Example applications
To illustrate how the use of IPD with MAIC can address the limi-
tations that arise for indirect comparisons without IPD, four ex-
ample applications are presented.
Indirect comparisons with IPD can resolve significant differences
in key baseline characteristics: vildagliptin versus sitagliptin in
Japanese patients with type II diabetes mellitus [22]
Vildagliptin and sitagliptin are two treatments for type II diabe-
tes that were recently approved for use in Japan. Both have been
associated with better glycemic control compared with placebo
or voglibose in randomized trials [23–29]. A systematic litera-
ture review of clinical trials in Japanese patients identified two
vildagliptin [25,26] and two sitagliptin [23,27] trials. The com-
mon comparators included placebo and voglibose. An indirect
comparison of aggregate data suggested that vildagliptin was
associated with a significantly greater absolute decrease in
mean % glycosylated hemoglobin A1c (Hb A1c) versus sitagliptin
difference0.17; 95% confidence interval [CI]:0.33 to0.01;
 0.024) in the voglibose-controlled trials but that the differ-
ence was not statistically significant in the placebo-controlled
trials (difference  0.20; 95% CI: 0.45 to 0.05; P  0.133). Sig-
nificant cross-trial baseline differences in mean Hb A1c, how-
ver, call into question the validity of the comparison based
nly on published aggregate data. Patients in the vildagliptin
rials had significantly lower mean Hb A1c at baseline than did
patients in the sitagliptin trials. Higher baseline Hb A1c has been
associated with greater postbaseline Hb A1c reduction in meta-
analyses of oral antihyperglycemics [30]. Although meta-re-
gression can adjust for baseline differences in aggregate trial
data, it can be unreliable with data from only four trials.
By using IPD from the vildagliptin trials, patients were selected
on the basis of inclusion/exclusion criteria specified in the sita-
gliptin trials and were reweighted to match exactly the baseline
characteristics reported for the sitagliptin trials, including the
baseline mean Hb A1c as well as age, sex, bodymass index, fasting
plasma glucose (FPG), and diabetes duration. After matching,
vildagliptin was associatedwith a significantly greater decrease in
Hb A1c compared with sitagliptin (Table 1). Compared with the
ndirect comparison based on only aggregate data, the treatment
ifference between vildagliptin and sitagliptin increased after
AIC, consistent with the expected effect of adjusting for baseline
b A differences. The use of IPD and MAIC in this example pro-1c
vided a more reliable comparison than did aggregate data alone,
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ulation.
Indirect comparisons with IPD can reduce sensitivity to the
effect measure: adalimumab versus etanercept in the
treatment of psoriasis [21]
Adalimumab (ADA) and etanercept (ETN) are the most commonly
used Food and Drug Administration –approved anti–tumor necro-
sis factors for the treatment of psoriasis. Both have demonstrated
efficacy relative to placebo for the reduction of psoriasis skin le-
sions in randomized trials [31–35]. A systematic literature review
identified two ADA trials with IPD [32,35] and one ETN trial [33]
ith summary results as having sufficiently comparable designs.
he efficacy outcome considered here, an improvement of 90% or
ore in the Psoriasis Area and Severity Index (PASI 90) score from
aseline to week 12, was higher in the ADA trials than in the ETN
rial (37.0% vs. 22.0%). The placebo-arm response rates, however,
ere also higher in the ADA trials (1.4% vs. 0.6%) (Table 2). Indirect
comparisons of these PASI 90 rates based only on aggregate data
can give results in opposing directions, depending on whether the
rate difference or odds ratio is used as the relative effect measure.
When using the rate difference, ADA is associated with an abso-
lute 14.2% greater rate of PASI 90 compared with ETN; when using
the odds ratio, ADA is associated with 13% lower odds of PASI 90
compared with ETN, with an odds ratio of 0.87. Such sensitivity to
the effect measure arises from differences in placebo-arm re-
sponse rates and is difficult to resolve by using only published
aggregate data. Although the odds ratio is often preferred for in-
direct comparisons, and has desirable statistical properties, there
Table 1 – Selected baseline characteristics and outcomes b
treatment of japanese patients with type 2 diabetes mellitu
Characteristics or
outcomes
Before matching
Vildagliptin trials25,26 Sitag
Baseline characteristics
Voglibose-controlled trials of vildagliptin 50mg bid (N363) or sita
Age [year; mean (SD)] 59.1 (9.9)* 60.
HbA1c [%; mean (SD)] 7.6 (0.9)† 7.
FPG [mg/dL; mean (SD)] 162.4 (31.3)‡ 149.
Placebo-controlled trials of vildagliptin 50mg bid (N148) or sitagl
Age [year; mean (SD)] 59.6 (8.3) 60.
HbA1c [%; mean (SD)] 7.4 (0.8)† 7.
FPG [mg/dL; mean (SD)] 161.4 (31.5)† 150.
Outcome: HbA1c during the 12-month outcomes period [ %, mean (9
Voglibose-controlled trials
Vildagliptin 50mg bid vs.
sitagliptin 50mg od
0.57 (0.69, 0.45) 0.4
Difference 0.17 (0.33, 0.01
Placebo-controlled trials
Vildagliptin 50mg bid vs.
sitagliptin 50mg od
1.19 (1.39, 0.99) 0.9
Difference 0.20 (0.45, 0.05)
Pooled
Difference of vildagliptin
50mg bid vs. sitagliptin
50mg od
0.18 (0.30, 0.06
Chi-squared tests for binary baseline characteristics and t-tests for c
parison of HbA1c during the 12-month outcome period, unweightedA
ANCOVA, analysis of covariance; bid, twice daily; HbA1c, FPG, fasting
* p  0.05.
† p  0.01, and
‡ p  0.001 for comparisons of vildagliptin vs. sitagliptin trials.is no evidence that it provides a bettermodel for cross-trial adjust-ment than the risk difference in this application to a small number
of trials.
After using MAIC with IPD for the ADA versus placebo trials
to remove observed differences in mean baseline characteris-
tics compared with the ETN versus placebo trial, the difference
in placebo-arm response rates was reduced to 0.9% versus 0.6%,
for the ADA and ETN trials respectively. Comparison of the
matched populations resulted in a consistently higher rate of
PASI 90 with ADA versus ETN (rate difference  14.8%; 95% CI
6.8%–22.8%; P  0.001), with a corresponding odds ratio of 1.34
indicating a 34% increase in the odds of PASI 90 with ADA versus
ETN. Thus, using IPD to match trial populations reduced the
sensitivity to the effect measure that would have limited an
indirect comparison based only on aggregate data.
Indirect comparisons with IPD can resolve differences in
outcome definitions: nilotinib versus dasatinib in newly
diagnosed chronic myelogenous leukemia chronic phase [36]
Nilotinib anddasatinib, both recently approvedby theFoodandDrug
Administration for the treatment of newly diagnosed chronic my-
elogenous leukemia (CML) In the chronic phase, have superior effi-
cacy compared with the previous standard of care, imatinib [37,38].
There are only two published trials of nilotinib or dasatinib for CML
chronic phase (ENESTnd and DASISION), each compared with ima-
tinib [39,40]. Although major molecular response (MMR) was re-
ported for both trials, each trial used a different definition for this
endpoint. The ENESTnd trial reported MMR at 12months, while DA-
SISION reported MMR by 12months. In addition, MMRwas assessed
at different times, which is important for assessing achievement by
and after matching-vildagliptin vs. sitagliptin in the
After matching
trials23,27 Vildagliptin trials25,26 Sitagliptin trials23,27
n 50mg od (N319)
0) 60.7 (10.0) 60.7 (10.0)
) 7.8 (0.9) 7.8 (0.9)
4) 149.4 (32.4) 149.4 (32.4)
50mg od (N145)
) 60.2 (8.7) 60.2 (8.7)
) 7.7 (0.9) 7.7 (0.9)
1) 150.4 (32.1) 150.4 (32.1)
I)]
.50, 0.30) 0.60 (0.72, 0.48) 0.40 (0.50, 0.30)
0.20 (0.36, 0.04)†
.17, 0.81) 1.55 (1.80, 1.30) 0.99 (1.17, 0.81)
0.56 (0.87, 0.25)‡
0.28 (0.42, 0.14)‡
uous baseline characteristics were used before matching; for com-
A beforematching andweightedANCOVAaftermatchingwere used
ma glucose; glycosylated haemoglobin; od, once daily.efore
s22.
liptin
glipti
7 (10.
8 (0.9
4 (32.
iptin
2 (8.7
7 (0.9
4 (32.
5% C
0 (0
)*
9 (1
)†
ontin
NCOV
plas12 months because some responses can be transient. In ENESTnd,
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it was assessed within 6 weeks after randomization and then at
months 3, 6, 9, and 12. Because of the different definitions and as-
sessment schedules, comparison of MMR outcomes in an indirect
comparisonusingaggregatedata couldbebiased. Basedsolelyon the
aggregate data, the treatments appeared to have similar efficacy; the
MMR at 12monthswas 44% for nilotinib, and theMMR by 12months
was 46% for dasatinib.
After using IPD from ENESTnd to compute MMR by 12 months in
that trial (using onlymonths 3, 6, 9, and 12), however, treatmentwith
nilotinib was associated with a significantly higher rate of MMR by
month12comparedwithdasatinib (56.8%vs. 45.9%; ratedifference
10.8%; 95% CI 2.2%–19.4%; P 0.014; Table 3) after adjusting for mul-
tiple baseline characteristics by using MAIC, including age, sex, CML
Table 2 – Selected baseline characteristics and outcomes b
Psoriasis21.
Characteristics or outcomes Before m
ADA trials32,35
(N1052)
Baseline characteristics
Age [year; mean (SD)] 43.9 (13.2)†
Psoriatic arthritis (%) 26.9†
Prior systemic or phototherapy (%) 62.2‡
Affected body surface area
[mean% (SD)]
25.9 (15.0)‡
Outcome: week 12 PASI response >90% (%)
PBO in ADA trials (n347) vs. PBO
in the ETN trial (n166)
1.4
ADA (n678) vs. ETN (n164) 37.0
Difference*
ADA, adalimumab; ETN, etanercept; PASI, Psoriasis Area and Severit
* Difference-in-difference of response rates: (ADA - PBO in ADA trial
† p  0.05.
‡ p  0.01, and
§ p  0.001 for comparisons of ADA vs. ETN trials.
Chi-squared tests for binary baseline characteristics and t-tests for c
chi-squared test was used for week 12 PASI response 90% after m
Table 3 – Selected baseline characteristics and outcomes b
treatment newly diagnosed CML-CP patients36.
Characteristics or outcomes Befor
Nilotinib trial39
(N273)
Baseline characteristics
Age (year)
Median 47
65 (%) 11
Eastern Cooperative Oncology Group
Performance Status (%)
0 88
1 12
Platelet count [median (103/mm3)] 419
Outcome: difference in major molecular response (MMR) by 12 mon
imatinib 400mg od in nilotinib trials vs.
imatinib in dasatinib trials
nilotinib 300mg bid vs. dasatinib 100mg od 9.4
For the comparison ofMMRby 12month, a chi-squared testwas used
Bid, twice daily, od, once daily, NR, not reported.
* p  0.05 for comparisons of nilotinib vs. dasatinib trials.duration, performance status, and laboratory markers associated
with CML severity. No difference was seen in the rate of MMR be-
tween the imatinib arms after matching (rate difference  1.2%;
95% CI 9.04% to 6.64%; P  0.77). This example shows the impor-
tance of identifying and reconciling differences in outcome defini-
tions in indirect comparisons.
Indirect comparisons using IPD can compare clinically relevant
dosages: guanfacine extended release versus atomoxetine in
children and adolescents with attention deficit/hyperactivity
disorder
Guanfacine extended release (GXR) and atomoxetine (ATX) are
two commonly used Food and Drug Administration–approved
and after matching – ADA vs. ETN in the Treatment of
ing After matching
ETN trial33
(N330)
ADA trials32,35
(N1052)
ETN trial33
(N330)
45.2 (11.6) 45.2 (11.6) 45.2 (11.6)
22.0 22.0 22.0
76.0 76.0 76.0
29.3 (19.3) 29.3 (19.3) 29.3 (19.3)
0.6 0.9 0.6
22.0 37.1 22.0
14.8 (6.8, 22.8)§
x; PBO, placebo.
TN - PBO in the ETN trial).
uous baseline characteristicswere used beforematching; aweighted
ing.
and after matching– nilotinib vs. dasatinib in the
tching After matching
Dasatinib trial40
(N259)
Nilotinib trial 39
(N273)
Dasatinib trial40
(N259)
46 46 46
8 8 8
82 82 82
18 18 18
448 448 448
(95% CI)]
1.2 (9.0, 6.6)
17.8)* 10.8 ( 2.2, 19.4)*
matching and aweighted chi-squared testwas used aftermatching.efore
atch
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944 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 0 – 9 4 7nonstimulants for the treatment of attention deficit/hyperac-
tivity disorder (ADHD). A systematic literature review identified
two trials with IPD for GXR [41,42] and four trials with summary
esults for ATX [43–46]. A key difference between these trials
as the assignment of dosages: the GXR trial randomized pa-
ients to fixed doses, regardless of body weight, whereas the
TX trial randomized patients to weight-based doses of 0.5 to
.0 mg/kg/d. Within the GXR trial, weight-based doses ranged
rom 0.01 to 0.17 mg/kg/d. Efficacy comparisons at doses con-
idered to be therapeutic alternatives are necessary to provide
eaningful comparative evidence to decision makers, but indi-
ect comparisons are difficult to conduct by using aggregate
hen outcomes are reported for fixed versus weight-based dos-
ng. By using IPD data from the GXR trials, patients were se-
ected if they met the inclusion/exclusion criteria of the ATX
rials and were expected to receive target doses of 0.09 to 0.12
g/kg/d [47]. The change in ADHD Rating Scale, Version IV
ADHD-RS-IV) total score from baseline to end point was com-
ared between this GXR-treated population and ATX treatment
t a target dose of 1.2 mg/kg/d [48]. Lower doses of GXR (0.046–
.075 and 0.075–0.090 mg/kg/d) were also considered as sensi-
ivity analyses. In each of the dosage groups, GXR-treated pa-
ients were reweighted to match the mean baseline
haracteristics of the ATX populations, including age, sex,
eight, ADHD subtype, baseline ADHD-RS-IV scores, and aver-
ge placebo outcome. Moreover, because only one ATX trial in-
luded a 1.2 mg/kg/d arm, a sensitivity analysis including all
TX arms with amaximum allowed dose of 1.2 mg/kg/d or more
as conducted, pooling data from all four ATX trials.
Before matching, patients treated with GXR had a greater per-
entage of the combined ADHD subtype versus those treated with
.2 mg/kg/d or more of ATX (73.2% vs. 69.3%). In unadjusted indi-
ect comparisons of these data, the ADHD-RS-IV score change
rom baseline was higher in each weight-based dosing group for
atients treated with GXR versus those treated with ATX 1.2 or 1.2
g/kg/d or more, respectively. The placebo arm in the GXR trials,
owever, also showed greater ADHD-RS-IV score reduction than
n the ATX trials (Table 4).
After matching, baseline characteristics and placebo-arm re-
ponses were identical between the two populations (Table 4). In
he base case, compared with ATX 1.2 mg/kg/d, GXR 0.09 to 0.12
g/kg/d was associated with a significantly greater reduction in
hemean ADHD-RS-IV total score (mean difference7.0; 95% CI
11.3 to 2.7; P  0.01). In the sensitivity analysis, GXR 0.075 to
.090 mg/kg/d was also associated with significantly greater re-
uction in the mean ADHD-RS-IV total score (mean difference 
6.0; 95%CI11.3 to0.7; P 0.05). Thiswas also true for GXR 0.09
o 0.12 and 0.046 to 0.075mg/kg/d comparedwith ATX 1.2mg/kg/d
r higher doses.
By using IPD, it was possible to select specific GXRpatientswith
oses that are considered therapeutic alternatives to ATX doses
hat have been investigated in randomized trials. Matching fur-
her adjusted for observed baseline characteristics and placebo
fficacy across trials to ensure a comparison across balanced trial
opulations.
Discussion
Through several example applications, this article has demon-
strated how the use of IPD and MAIC can provide timely and reli-
able comparisons between treatmentswhen indirect comparisons
based only on published aggregate data are limited by cross-trial
differences. Each of the example applications has illustrated a dif-
ferent benefit of using available IPD andMAIC. First, IPD andMAIC
removedmean differences in a key baseline characteristic (Hb A1c)
in diabetes trials. Second, the use of IPD and MAIC reduced the
differences in placebo-arm response rates among psoriasis trials,rendering the indirect comparison less sensitive to the choice of a
relative effect measure (risk difference or odds ratio). Third, using
IPD resolved differences in study protocols and end-point defini-
tions for MMR in CML trials. Finally, the use of IPD and MAIC al-
lowed comparison of clinically relevant dosages with adjustment
for baseline symptom scores in ADHD trials.
All these examples have included relatively small numbers of
trials. Such settings often arise as new treatments become avail-
able. In some cases, as in the CML example, only one trial is avail-
able for each treatment. These settings are particularly challeng-
ing for methods based on aggregate data because having a small
number of trials may increase the chances that trials of one treat-
ment have significantly different characteristics or designs than
do trials of another treatment. The underlying model for indirect
comparisons based on aggregate data assumes that observed tri-
als represent an exchangeable randomsample fromanunderlying
distribution of all possible trials of the studied treatments
[1,2,49,50]. But even if this assumption holds true, a random sam-
ple of a small number of trials can risk substantial imbalance
when trial-level heterogeneity is high. To the extent that observed
factors such as inclusion/exclusion criteria, patient baseline char-
acteristics, and outcome definitions can explain cross-trial heter-
ogeneity, the use of IPD andMAIC can improve the reliability of the
indirect comparisons compared with using aggregate data only.
Many researchers can access IPD for some treatments of in-
terest in a comparative analysis, but accessing IPD for all treat-
ments is often not possible. Without an appropriate methodol-
ogy for combining IPD with publicly available summary data,
IPD has remained a largely untapped resource for CER. By uti-
lizing IPD available only for one comparator treatment, MAICs
could substantially increase the availability and reliability of
comparative evidence. The approach could be especially helpful
for new treatments with small number of trials, for which many
treatment and reimbursement decisions are currently based
only on informal (naive) indirect comparisons across trials or on
anchor-based indirect comparisons subject to the limitations
described above. Payers or health technology assessment au-
thorities responsible for formulary policy, who routinely re-
quest indirect comparisons and economic models from manu-
facturers, can consider MAIC as a way to fill evidence gaps and
increase the reliability of the comparative evidence on which
they base their decisions. A common goal of payers in synthe-
sizing comparative evidence is to ensure that all relevant and
available data are utilized. When IPD are available, as in manu-
facturer submissions, these data can be utilized with MAIC and,
as shown the examples above, can be highly relevant.
Limitations
Indirect comparisons, like any comparison of nonrandomized
treatment groups, can be biased by both observed and unobserved
cross-trial differences. Although the use of IPD and MAIC can re-
move or reduce observed cross-trial differences, unobserved dif-
ferences may result in residual confounding. Comparing placebo-
arm (or other common comparator arm) outcomes across trials
provides an opportunity to detect some residual confounding.
Greater differences in placebo-arm outcomes indicate a greater
chance of important unobserved differences between trials and
greater sensitivity to the choice of a relative effect measure (e.g.,
odds ratio vs. risk difference). Even when placebo-arm outcomes
arewell balanced between trials, however, an indirect comparison
may be biased by unobserved factors that impact treatment- but
not placebo-arm outcomes (e.g., baseline factors impacting adher-
ence). Only a well-controlled head-to-head randomized trial can
avoid unobserved confounding.
Practical limitations of IPD and MAIC are important. First, it is
not always possible to match outcome definitions or inclusion/
exclusion criteria by using IPD. For example, if a published trial
b
t
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months, and the trial with IPD has assessments only every 6
months, a fair comparison may be impossible. Likewise, if the
published trial enrolled patients of all ages, but IPD are available
only for patients younger than 65 years, it will be impossible to
fully match the age distribution of the published trial. Second,
unlike traditional propensity score weighting, the availability of
only aggregate data for some trials in an MAIC prevents the use of
existing methods for checking the fit and calibration of the pro-
pensity score model. Despite this limitation, balance in the aver-
age baseline characteristics can be verified in MAIC, as in tradi-
tional propensity score matching. Third, the ability to adjust for
multiple baseline factors depends on having a sufficient number
of patients in trials with IPD. In general, matching larger numbers
Table 4 – Selected baseline characteristics and outcomes b
ADHD.
Characteristics or outcomes Before
GXR trials41,42
(N403)
Baseline characteristics 10.4 (2.6)
Age [years; mean(SD)] 74.2
Male (%)
ADHD subtype (%) 24.3
Inattentive 2.5
Hyperactive-impulsive 73.2
Combined
ADHD-RS-IV scores [ mean (SD)]
Total score 39.4 (8.5)
Hyperactivity/impulsivity subscale score 17.4 (6.5)
Inattentive subscale score 22.0 (4.1)
Outcome: ADHD-RS-IV Total scores change from baseline [Mean (95
Placebo in GXR trials (n136) vs. placebo
in the ATX trial† (n83)
10.6 (12.8, 8.4)
Difference 4.8 (
GXR 0.046-0.075 mg/kg/day (n147) vs.
ATX 1.2 mg/kg/day† (n84)
17.9 (20.1, 15.7)
Difference 4.3 (
GXR 0.075-0.090 mg/kg/day (n46) vs. ATX
1.2 mg/kg/day† (n84)
18.5 (22.6, 14.4)
Difference 4.9 (
GXR 0.09-0.12 mg/kg/day (n82) vs. ATX
1.2 mg/kg/day† (n84)
22.8 (25.3, 20.3)
Difference 9.2 (
Placebo in GXR trials (n136) vs. placebo
in ATX trials (n348)
10.6 (12.8, 8.4)
Difference 4.8 (
GXR 0.046-0.075 mg/kg/day (n147) vs.
ATX 1.2 mg/kg/day (n506)
17.9 (20.1, 15.7)
Difference 3.3 (
GXR 0.075-0.090 mg/kg/day (n46) vs. ATX
1.2 mg/kg/day (n506)
18.5 (22.6, 14.4)
Difference 3.9
GXR 0.09-0.12 mg/kg/day (n82) vs. ATX
1.2 mg/kg/day (n506)
22.8 (25.3, 20.3)
Difference 8.2 (
GXRguanfacine extended-release (Intuniv) ; ATX  atomoxetine (St
* Unspecified and hyperactive-impulsive categories were combined
† Only one ATX trial [46] included ATX arm 1.2 mg/kg/day; the corres
‡ p  0.05.
§ p  0.01, and
 p  0.001 for comparisons of GXR vs ATX trials. Chi-squared test
characteristics were used before matching; for comparison of AD
matching and weighted t-tests were used after matching.of average baseline characteristics and adjusting for greater cross- atrial baseline differences will requiremore extremeweights andwill
reduce theeffective sample size. Inpractice, this is lessof a limitation
than faced by meta-regression, which requires the number of trials,
rather than thenumber of patients, to exceed thenumber of baseline
characteristics used for adjustment. However, in extreme cases, as
when there aremore baseline characteristics thanpatients, it should
be noted that MAIC cannot be used to match all baseline character-
istics. Similarly, if there are extreme differences inmultiple baseline
characteristics (e.g., in some trials, 90% are treatment naive and 5%
are aged65 years, yet in other trials, only 10% are treatment naive
and 60% are aged 65 years), it may be impossible to balance all
aseline characteristics by using MAIC, or any other method, if the
rials populations truly have limited overlap.
MAICmay also be applied to single-arm trials, or trials without
and after matching – GXR vs. ATX in the treatment of
ching After matching
TX trials43,44,45,46
(N873)
GXR trials41,42
(N403)
ATX trials43,44,45,46
(N873)
10.2 (2.0) 10.2 (2.0) 10.2 (2.0)
73.4 73.4 73.4
28.6 28.6 28.6
2.1* 2.1 2.1*
69.3 69.3 69.3
39.5 (8.7) 39.5 (8.7) 39.5 (8.7)
17.6 (6.6) 17.6 (6.6) 17.6 (6.6)
21.9 (3.9) 21.9 (3.9) 21.9 (3.9)
]
5.8 (8.2, 3.4) 5.8 (8.2, 3.4) 5.8 (8.2, 3.4)
1.6)§ 0
13.6 (16.5, 10.7); 17.3 (19.8, 14.8) 13.6 (16.5, 10.7)
0.6)§ 3.7 (7.6, 0.2)
13.6 (16.5, 10.7) 19.6 (23.9, 15.3) 13.6 (16.5, 10.7)
, 0.2) 6.0 (11.3, 0.7)‡
13.6 (16.5, 10.7) 20.6 (23.7, 17.5) 13.6 (16.5, 10.7)
5.3)‡ 7.0 (11.3, 2.7)§
5.8 (7.0, 4.6) 5.8 (7.0, 4.6) 5.8 (7.0, 4.6)
2.3)§ 0
14.6 (15.8, 13.4) 18.9 (21.3, 16.5) 14.6 (15.8, 13.4)
0.8)§ 4.3 (6.8, 1.8)§
14.6 (15.8, 13.4) 17.7 (21.8, 13.6) 14.6 (15.8, 13.4)
, 0.4) 3.1 (7.2, 1.0)
14.6 (15.8, 13.4) 22.2 (24.7, 19.7) 14.6 (15.8, 13.4)
5.5) 7.6 (10.3, 4.9)
ra).
X trials.
ing placebo arm in the same trial was used for this analysis.
binary baseline characteristics and t-tests for continuous baseline
RS-IV total scores change from baseline, t-tests were used beforeefore
mat
A
% CI)
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ratte
for AT
pond
s for
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946 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 0 – 9 4 7surgical interventions, rare diseases, and oncology trials for pa-
tients with poor prognosis, the use of IPD may be the only way to
adjust for cross-trial differences and should be preferred over na-
ive unadjusted comparisons. The absence of a common compar-
ator arm, however, should be noted as an important limitation,
because validation of the matching or the use of relative effect
measures will not be possible.
Finally, when using IPD and MAIC, there may be trials identi-
fied in a systematic review, either with IPD or with only aggregate
data available, that cannot be included in the analysis because of
irreconcilable differences in design or patient characteristics. Al-
though the consideration of all available evidence is an important
guiding principle for any evidence synthesis, there is a trade-off
between includingmore evidence and reducing heterogeneity. For
indirect comparisons, heterogeneity across trials can result in
confounding and bias. Avoidance of bias should be a primary goal
of indirect comparisons, and the need to reduce bias should be
considered as thoroughly as the need to include all trials. In cases
where the inclusion or exclusion of a trial is questionable, sensi-
tivity analyses should be conducted with and without it.
Conclusion
While randomized trials are the gold standard for CER, they are not
always available for clinically and economically important treat-
ment comparisons, especiallywhennovel therapies becomeavail-
able. Many researchers engaged in CER can access IPD for certain
trials, but these data have not been widely used for indirect com-
parisons. The examples presented in this article have shown that
by using IPD from one treatment and published aggregate data
from another treatment, MAICs can provide greater adjustment
for observed cross-trial differences compared with indirect com-
parisons based only on published aggregate data. In this way, the
use of IPD and MAIC can provide decision makers with timely and
reliable comparative evidence.
Source of financial support: Shire Development LLC, provided
funding to Analysis Group, Inc., to perform this study. Although
the sponsor was involved in the design, collection, analysis, inter-
pretation, and fact checking of information, the content of this
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